Overactive Bladder

Search with Google Search with Bing
Information
Disease name
Overactive Bladder
Disease ID
Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT04936464 Active, not recruiting N/A Transcutaneous Tibial Nerve Stimulation for Urgency Urinary Incontinence September 20, 2021 June 30, 2024
NCT05282069 Active, not recruiting Phase 3 A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder May 12, 2022 May 2024
NCT06181019 Active, not recruiting Phase 1 Acupuncture Combined With Mirabegron in the Treatment of OAB December 1, 2021 December 31, 2024
NCT05308979 Active, not recruiting Phase 4 Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial May 1, 2022 March 31, 2024
NCT05241379 Active, not recruiting N/A AURA-2: Augmenting Urinary Reflex Activity November 30, 2022 April 2024
NCT05494567 Active, not recruiting Phase 4 Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB November 8, 2021 August 2022
NCT05226286 Active, not recruiting N/A Evaluation of Implantable Tibial Neuromodulation Pivotal Study January 31, 2022 April 2025
NCT03556891 Active, not recruiting N/A Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence September 4, 2018 April 28, 2024
NCT05067478 Active, not recruiting Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB) October 28, 2021 September 2024
NCT00224146 Completed Phase 4 Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder May 2004 May 2005
NCT00231491 Completed Phase 2 Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder. November 2005 April 2010
NCT00238680 Completed N/A Programmable Timer in the Bladder Rehabilitation Treatment of OAB March 2005 April 2007
NCT00282490 Completed N/A Surface Nerve Stimulation Treatment for OAB in Children February 2006 March 2008
NCT00290563 Completed Phase 2 Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003) February 21, 2006 September 24, 2007
NCT00311376 Completed Phase 3 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder August 2006 May 2010
NCT00321477 Completed Phase 2 A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder December 2005 February 2007
NCT00337090 Completed Phase 2 A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON) March 2007
NCT00337558 Completed Phase 4 A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) May 2006 May 2007
NCT00343486 Completed Phase 2 Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms May 2006
NCT00350636 Completed Phase 3 A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo June 2006 May 2007
NCT00425100 Completed Phase 3 A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients January 2007 October 2007
NCT00427596 Completed Phase 1 A Two-Part Study to Determine: Best Medication Formulation and Food Effect January 2007 August 2007
NCT00431041 Completed Phase 4 Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) December 2006 February 2008
NCT00441428 Completed Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity February 2006
NCT00444925 Completed Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB) April 2007 July 2008
NCT00448175 Completed Phase 4 Overactive Bladder Innovative Therapy Trial (OrBIT) June 2006 October 2008
NCT00461292 Completed Phase 3 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder May 2007 April 2010
NCT00465894 Completed N/A Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms April 2007 December 2011
NCT00478881 Completed Phase 2 A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function August 2007 November 2008
NCT00481728 Completed Phase 1 Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate. June 2007 December 2008
NCT01125722 Completed N/A Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB) April 2010 March 2011
NCT00138723 Completed Phase 3 Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome October 2003 February 2005
NCT00168454 Completed Phase 2 A Research Study for Patients With Overactive Bladder July 2005 June 2008
NCT00171184 Completed Phase 4 Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder April 2005 June 2006
NCT00174798 Completed Phase 2 MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence. May 2005 May 2006
NCT00189800 Completed Phase 3 A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
NCT00212706 Completed Phase 2 Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan October 2001
NCT00212732 Completed Phase 3 Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan October 2003
NCT00220389 Completed Phase 2 Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase June 2003 June 2007
NCT01738464 Completed Microbiomes of Pelvic Pain June 2012 July 8, 2023
NCT01739946 Completed Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients. October 2012 December 2016
NCT01745094 Completed Phase 4 A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients October 1, 2012 July 23, 2013
NCT01747577 Completed Phase 4 Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate) December 4, 2012 October 24, 2013
NCT01767519 Completed Phase 3 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence March 1, 2013 March 18, 2015
NCT01768910 Completed N/A Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction December 2011 December 2018
NCT01824420 Completed Phase 4 Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome March 2013 February 2017
NCT01833663 Completed Phase 4 Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women October 2011 October 2013
NCT01848366 Completed N/A Utilization of the BIOWAVE Device to Treat Overactive Bladder May 2013 August 2014
NCT01868516 Completed Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder May 2013 June 2014
NCT01870037 Completed Phase 1 Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer January 2013 February 17, 2018
NCT01898624 Completed Specified Drug Use-results Survey of Betanis Tablets December 4, 2012 January 10, 2018
NCT01901120 Completed Long-Term Specified Drug Use-results Survey of Betanis Tablets October 2012 September 2016
NCT01919047 Completed Drug Use-Results Survey of Betanis Tablets in Japan April 2012 July 2014
NCT01925456 Completed Phase 1 Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder May 2011 December 2013
NCT01933074 Completed Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency January 2013 June 2014
NCT01945489 Completed Phase 4 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder October 28, 2013 January 5, 2017
NCT01955408 Completed Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment September 30, 2013 December 31, 2016
NCT01972841 Completed Phase 3 This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder November 5, 2013 October 22, 2015
NCT02040519 Completed N/A Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation January 2014 February 6, 2017
NCT02045862 Completed Phase 3 A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder March 17, 2014 September 8, 2016
NCT02107820 Completed N/A Does Bladder Training Improve the Efficacy of Nerve Stimulation in Women With Refractory Overactive Bladders July 24, 2014 March 25, 2019
NCT02143570 Completed Phase 3 Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women May 2014 April 2016
NCT02180048 Completed N/A "The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women" July 2014 September 20, 2018
NCT02180997 Completed Phase 1 Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin July 2014 March 2015
NCT02197533 Completed N/A Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions July 2014 September 1, 2019
NCT02202031 Completed N/A Controlling Urgency Through Relaxation Exercises September 2014 March 2018
NCT02211846 Completed Phase 1 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder September 21, 2014 September 21, 2015
NCT02240459 Completed Phase 2 A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment August 2016 January 31, 2020
NCT02251054 Completed N/A Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder October 2012 October 2013
NCT02271607 Completed N/A The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients October 2014 December 2015
NCT02320773 Completed A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice November 25, 2014 July 27, 2016
NCT02327936 Completed Phase 3 Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children December 2014 August 2018
NCT02377765 Completed N/A Use of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Maintaining OAB Symptoms Improvement. February 2014 October 2016
NCT02386072 Completed A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) January 5, 2015 August 4, 2017
NCT02396160 Completed N/A The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence August 2013 May 2015
NCT02447367 Completed Phase 1 Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers July 2015 December 2015
NCT02468375 Completed Phase 4 Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. June 2015 December 2017
NCT02468830 Completed Phase 3 Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder April 2013 March 2016
NCT02476175 Completed Phase 3 Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder April 2013 June 2016
NCT02485067 Completed Phase 3 Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB January 2015 September 2016
NCT02494349 Completed Phase 1 The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers. August 2015 December 2015
NCT02495389 Completed Phase 4 Mirabegron and Urinary Urgency Incontinence January 28, 2015 January 29, 2019
NCT02502838 Completed The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair May 2015 June 30, 2017
NCT02511717 Completed N/A A Trial of Transcutaneous Nerve Stimulation for OAB January 2016 April 1, 2019
NCT02524769 Completed N/A The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides December 2015 June 2017
NCT02526979 Completed Phase 1 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) December 17, 2015 September 30, 2016
NCT02536976 Completed Phase 4 Mirabegron in Parkinson Disease and Impaired Cognition December 2015 August 1, 2018
NCT02540798 Completed Do Patient Anxiety Levels Decrease Urodynamic Test Reproducibility? July 2015 April 2016
NCT02568774 Completed N/A Acupuncture on Post-Stroke Overactive Bladder August 2015 August 2018
NCT02570035 Completed Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease December 2012 March 2015
NCT02590250 Completed A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India December 16, 2015 August 7, 2017
NCT02600715 Completed Phase 4 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository November 2015 June 26, 2017
NCT02601287 Completed Phase 4 A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients November 2015 July 2016
NCT02614482 Completed Phase 3 Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. October 2015 August 2018
NCT02620410 Completed N/A Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System (RELAX-OAB) June 2016 January 2022
NCT02622555 Completed Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists August 2013 November 2015
NCT02656173 Completed Phase 4 A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) January 25, 2016 July 21, 2017
NCT02657057 Completed N/A Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB November 2015 March 2017
NCT02667470 Completed Phase 4 Reproducibility Study of OABSS and Its Response to Treatment September 2009 May 2013
NCT02670486 Completed N/A Audiovisual Stimulus During Urodynamics August 2014 June 2016
NCT02677753 Completed N/A Percutaneous Nerve Evaluation With Fluoroscopy Versus Without April 2016 April 2019
NCT02715024 Completed Phase 4 Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms September 2007 April 2011
NCT02735499 Completed Phase 2 Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB) March 2016 October 2016
NCT02757768 Completed Phase 4 A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) June 13, 2016 September 11, 2018
NCT02790307 Completed Phase 2 Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome January 2013 December 2013
NCT02835846 Completed Phase 4 Investigation of the Effect of the Female Urinary Microbiome on Incontinence September 2016 May 2018
NCT02852317 Completed Urinary Markers of Detrusor Overactivity in Spina Bifida Patients March 16, 2015 July 17, 2017
NCT02857816 Completed N/A PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB September 2016 November 21, 2017
NCT02916693 Completed Phase 1/Phase 2 Mirabegron For Erectile Dysfunction August 1, 2017 January 1, 2020
NCT02940314 Completed Phase 1 Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers March 2016 May 2016
NCT03017170 Completed Phase 1 Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB April 2016 July 2018
NCT03023241 Completed N/A Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis December 2004 July 2021
NCT03057158 Completed Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study May 1, 2017 March 11, 2020
NCT03104101 Completed N/A Transcutaneous Posterior Tibial Nerve Electrostimulation With Low Dose Trospium Chloride in OAB in Females November 1, 2014 March 5, 2016
NCT03106623 Completed Phase 2 Study of ONO-8577 in Patients With Overactive Bladder April 7, 2017 September 26, 2017
NCT03149809 Completed Phase 3 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease March 1, 2018 September 8, 2023
NCT03175029 Completed Phase 2 Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. August 1, 2017 March 27, 2020
NCT03371342 Completed Phase 1 Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder December 13, 2017 September 5, 2018
NCT03390790 Completed Phase 4 Lidocaine for Pain After Urodynamic Testing January 25, 2018 March 29, 2019
NCT03451175 Completed Reproductibility of Cystometry in Multiple Sclerosis Patient July 2, 2017 January 1, 2018
NCT03473782 Completed Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study October 12, 2015 August 8, 2023
NCT03475706 Completed Phase 2 Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women February 19, 2018 January 30, 2019
NCT03477214 Completed Tactile Imaging and Electromyography December 24, 2017 March 15, 2020
NCT03492281 Completed Phase 3 A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) March 26, 2018 February 4, 2019
NCT03500146 Completed Sexual Function Trial of Overactive Bladder: Medication Versus PTNS January 30, 2017 September 30, 2019
NCT03544554 Completed N/A Training and Counseling Program for Overactive Bladder Treatment January 1, 2015 March 1, 2017
NCT03547518 Completed N/A Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation March 13, 2018 November 17, 2022
NCT03558919 Completed Phase 4 Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder January 1, 2017 December 30, 2017
NCT03566134 Completed Phase 2 A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder July 10, 2018 December 27, 2019
NCT03575702 Completed Phase 3 Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. July 18, 2016 September 1, 2017
NCT03583372 Completed Phase 3 An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). June 14, 2018 July 25, 2019
NCT03594058 Completed Phase 2 A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) July 9, 2018 May 2, 2019
NCT03595215 Completed N/A Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home September 10, 2018 September 17, 2019
NCT03625492 Completed N/A Fluids Affecting Bladder Urgency and Lower Urinary Symptoms August 7, 2018 September 17, 2019
NCT03625843 Completed N/A Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing September 29, 2016 April 30, 2018
NCT03643380 Completed Phase 1 Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence August 17, 2017 January 30, 2018
NCT03655054 Completed N/A eCoin for OAB Feasibility Follow-on Study March 13, 2019 September 12, 2022
NCT03662893 Completed N/A Behavioural Therapy With Checklist for Overactive Bladder January 1, 2015 April 15, 2018
NCT03801239 Completed Reliability of Polish-Version Overactive Bladder Syndrom Scores (OABSS) June 1, 2017 December 31, 2018
NCT03817931 Completed Phase 4 Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder August 5, 2019 February 26, 2022
NCT03874780 Completed N/A Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder January 29, 2019 March 31, 2019
NCT03902080 Completed Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) March 26, 2019 June 15, 2023
NCT03904407 Completed N/A Optimizing Overactive Bladder Treatment June 1, 2019 May 1, 2020
NCT03946124 Completed Phase 4 Fall Prevention in Older Adults With OAB July 25, 2015 July 19, 2017
NCT04016324 Completed N/A InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study November 28, 2019 October 9, 2020
NCT04063852 Completed PTNS on Urinary and Global Quality of Life in MS Patients February 27, 2019 November 27, 2022
NCT04068025 Completed N/A Information, Motivation, Behavioral Skills Model on Urinary Incontinence and Quality of Life in Men February 1, 2018 February 1, 2019
NCT04103450 Completed Phase 3 Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) September 19, 2019 July 29, 2022
NCT04115228 Completed N/A Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS) October 9, 2019 March 3, 2021
NCT04120545 Completed N/A Effectiveness of Microcurrents Therapy in Overactive Bladder. November 4, 2019 December 4, 2021
NCT04124939 Completed Phase 4 Is 10 Injections of Bladder Botox Less Painful Than 20 Injections? November 10, 2019 February 23, 2023
NCT04155593 Completed In-office Assessment of Voiding Function Following Botox Injection for Overactive Bladder November 8, 2019 July 15, 2020
NCT04186442 Completed Phase 1 Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder May 12, 2020 October 26, 2021
NCT04197466 Completed N/A Comparison of Different Treatments for Overactive Bladder Syndrome December 6, 2019 April 7, 2020
NCT04265781 Completed Phase 1 Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants February 15, 2020 September 20, 2020
NCT04270526 Completed Phase 4 Minimizing Pain During Office Intradetrussor Botox Injection August 15, 2020 June 30, 2023
NCT04309890 Completed Arabic Translation and Validation of the (Overactive Bladder Symptom Score) OABSS February 1, 2019 June 30, 2019
NCT04369404 Completed N/A Impact of Decision Aids in Urogynecology February 1, 2019 June 1, 2019
NCT04423744 Completed Phase 1 Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants June 18, 2020 January 21, 2021
NCT04437108 Completed N/A Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO July 4, 2020 July 21, 2022
NCT04454424 Completed Phase 1 Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function July 23, 2020 December 15, 2021
NCT04470765 Completed N/A Transcutaneous Tibial Nerve Stimulation: the ZIDA Device Equivalence September 15, 2020 December 31, 2020
NCT04471337 Completed Phase 1 Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function August 12, 2020 May 6, 2021
NCT04477265 Completed N/A Efficacy of Biofeedback PFMT and Medication in Women With Overactive Bladder June 16, 2016 December 24, 2021
NCT04479709 Completed The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections January 1, 2021 June 30, 2022
NCT04485585 Completed Phase 1 A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. July 20, 2020 August 26, 2020
NCT04487431 Completed Phase 1 A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B) August 5, 2020 February 11, 2021
NCT04534491 Completed Phase 3 Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream. May 25, 2010 June 22, 2011
NCT04534946 Completed A Pilot Study Evaluating the Usability of the Oabi Mobile Application March 20, 2017 December 31, 2019
NCT04545580 Completed Phase 2 Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) September 16, 2020 January 21, 2022
NCT04547920 Completed N/A FREEOAB Study for Overactive Bladder January 11, 2021 June 15, 2023
NCT04570605 Completed N/A Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population April 1, 2019 July 1, 2020
NCT04599283 Completed N/A BE Technologies Mobile Uroflowmetry Validation Study August 18, 2020 February 25, 2021
NCT04619238 Completed Reliability of KHQ and ICIQ-SF in Assessing Urinary Incontinence Effects in Polish Women June 1, 2017 January 10, 2019
NCT04626960 Completed ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients June 5, 2019 June 7, 2020
NCT04681625 Completed N/A Evaluation of Silodosin and Pelvic Floor Muscle Training in Men With Benign Prostatic Hyperplasia and Overactive Bladder January 11, 2021 September 30, 2022
NCT04734301 Completed N/A Intravaginal Electrical Stimulation With Different Treatment Frequency in Women With Idiopathic Overactive Bladder February 5, 2021 July 15, 2021
NCT04758247 Completed N/A Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms October 28, 2021 December 8, 2023
NCT04791111 Completed AQUA: Anticholinergic Side Effects QUestionnAire January 1, 2020 August 31, 2021
NCT04873271 Completed N/A Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study May 11, 2021 July 8, 2022
NCT04907032 Completed Phase 4 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study) October 1, 2021 April 15, 2023
NCT04910555 Completed Strong Desire to Void and Balance in Older Women With Overactive Bladder May 26, 2021 July 21, 2022
NCT04917315 Completed Phase 3 To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder May 21, 2020 August 18, 2021
NCT04999657 Completed N/A Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder Symptoms August 26, 2021 December 15, 2022
NCT05013593 Completed N/A Red Clover Isoflavones in Postmenopausal Women With Urge Urinary Incontinence and Overactive Bladder July 15, 2019 October 20, 2021
NCT05117918 Completed N/A Overactive Bladder Telemedicine Non-inferiority Trial July 1, 2021 August 31, 2023
NCT05162833 Completed N/A Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms February 20, 2022 December 8, 2023
NCT05170100 Completed N/A Evaluating a Digital Intervention for Overactive Bladder September 1, 2021 November 7, 2021
NCT05250245 Completed Phase 4 Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome June 1, 2020 January 1, 2022
NCT05330117 Completed N/A Nerve Stimulation Using a TENS to Provide Pain Relief During Surgery for Overactive Bladder December 14, 2020 March 3, 2022
NCT05463822 Completed Early Phase 1 Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder June 20, 2019 September 27, 2021
NCT05464589 Completed N/A Effects of Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Adults August 10, 2021 July 25, 2022
NCT05557175 Completed N/A Repetitive Transcranial Magnetic Stimulation (rTMS) on Neurogenic Overactive Bladder in Stroke November 9, 2022 January 10, 2024
NCT05677841 Completed N/A Effects of Spinal Stabilization Exercises Focusing on the Pelvic Floor in Women With Overactive Bladder January 15, 2023 May 25, 2023
NCT05709990 Completed N/A Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children January 15, 2023 June 15, 2023
NCT05719285 Completed Phase 4 Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection December 6, 2022 June 8, 2023
NCT05783219 Completed Phase 2 Lidocaine Patches Prior to Percutaneous Nerve Evaluation May 1, 2023 April 1, 2024
NCT06024005 Completed N/A Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder April 18, 2023 May 24, 2023
NCT06123364 Completed N/A Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder October 14, 2019 October 1, 2023
NCT06184334 Completed N/A Management of OAB in Female Patients . September 14, 2022 December 1, 2023
NCT06250543 Completed Phase 4 Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder August 14, 2018 November 25, 2022
NCT06345677 Completed N/A Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects June 9, 2023 February 1, 2024
NCT06458556 Completed N/A Transvaginal Radiofrequency Ablation for Overactive Bladder June 19, 2023 May 30, 2024
NCT00501267 Completed Phase 1 A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder June 2007 August 2007
NCT00512785 Completed Phase 3 Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder August 2007
NCT00534521 Completed Phase 3 Posterior Tibial Nerve Stimulation vs. Sham September 2007 September 2007
NCT00536484 Completed Phase 3 Fesoterodine Flexible Dose Study August 2007 March 2008
NCT00547378 Completed Phase 4 InSite for Over Active Bladder October 2007 August 2016
NCT00553657 Completed Phase 1 The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder August 2007 January 2008
NCT00561951 Completed Phase 2 Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder. November 2007 January 2009
NCT00564226 Completed Phase 2 SSR240600C Treatment in Women With Overactive Bladder November 2007 February 2009
NCT00583219 Completed Phase 1/Phase 2 Botulin-A Toxin Instillations and Overactive Bladder March 2006 May 2008
NCT00603343 Completed Phase 3 Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence June 2004 December 2006
NCT00611026 Completed Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder. February 2008 October 2009
NCT00648310 Completed Phase 2/Phase 3 Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity January 2004 December 2007
NCT00658684 Completed Phase 3 Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder. February 2008 August 2009
NCT00685113 Completed Phase 3 A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder May 2008 March 2010
NCT00691093 Completed Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy July 2008 June 2009
NCT00706407 Completed N/A Uro-NIRS Clinical Study April 2008 May 2010
NCT00714792 Completed Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections? June 2008 March 2009
NCT00730535 Completed Phase 4 Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients August 2006 July 2009
NCT00746681 Completed Phase 2 Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder December 2005 November 2006
NCT00768521 Completed Phase 1 A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) September 3, 2008 January 19, 2009
NCT00771264 Completed Phase 4 Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms September 2008 June 2009
NCT00771394 Completed Phase 4 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia October 2008 January 2010
NCT00775281 Completed Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC. October 2006 April 2010
NCT00782769 Completed Phase 3 A Safety Extension Study of DR-OXY-301 September 2008 July 2010
NCT00786448 Completed Post Marketing Surveillance Study on Emselex After Launch in Germany January 2005 February 2006
NCT00793611 Completed N/A Hypnotherapy for Treatment of Overactive Bladder November 2008 March 2010
NCT00795925 Completed Phase 2 Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder October 2004 December 2005
NCT00836381 Completed Phase 4 Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder February 2009 January 2012
NCT00856570 Completed Phase 1 A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects September 2008 December 2008
NCT00857896 Completed Phase 2 Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years March 2009 December 2010
NCT00862745 Completed Phase 4 Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES) January 2009 May 2011
NCT00863551 Completed Phase 4 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial April 2009 August 2009
NCT00876421 Completed Phase 2 Study of ONO-8539 in Patients With Overactive Bladder April 2009
NCT00876447 Completed Phase 3 A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis January 1, 2009 September 4, 2013
NCT00879398 Completed Toviaz Post Marketing Surveillance Study November 2009 August 2014
NCT00883818 Completed Phase 4 Microorganism in Overactive Bladder Patients January 2007 December 2007
NCT00884104 Completed Phase 4 A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks March 2009 December 2010
NCT00892450 Completed N/A Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease May 2009 September 2014
NCT00901251 Completed Reproducibility Study of Over Active Bladder Symptom Score [OABSS] January 2009 May 2009
NCT00902421 Completed Phase 4 Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients January 2007 July 2009
NCT00903045 Completed Phase 4 Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder January 2005 August 2006
NCT00910520 Completed Phase 3 Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence September 2009 August 2011
NCT00910845 Completed Phase 3 Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence September 2009 July 2011
NCT00911937 Completed Phase 4 A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency August 2009 September 2011
NCT00915525 Completed Phase 3 Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence February 1, 2010 August 5, 2014
NCT00921245 Completed FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period June 2007 February 2009
NCT00922506 Completed Phase 4 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) May 2009 June 2014
NCT00928070 Completed Phase 4 A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder September 2009 September 2011
NCT00932022 Completed Phase 4 Trospium Chloride XR in Obese Female Patients With Overactive Bladder July 2009 December 2011
NCT00943735 Completed This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder July 2009 November 2010
NCT00943904 Completed N/A Comparison of Motor and Sensory Response With Interstim Stimulation July 2009 February 2012
NCT00979472 Completed Phase 4 Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency April 2009 June 2010
NCT00985387 Completed Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients August 2009 August 2011
NCT01004315 Completed Phase 3 A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
NCT01047046 Completed Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder January 2008 December 2009
NCT01089751 Completed Phase 4 Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily March 2010 June 2012
NCT01093534 Completed Phase 4 Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. January 2010 June 2011
NCT01122550 Completed Reproducibility Study of Overactive Bladder Symptom Score [OABSS] September 2009 August 2010
NCT01122563 Completed A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment September 2009 January 2011
NCT00131573 Completed Phase 3 An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome May 2004 December 2012
NCT01127126 Completed Phase 2 Bryophyllum Versus Placebo for Overactive Bladder December 2010 January 2012
NCT01130415 Completed Screening Method in Sacral Neuromodulation May 2002 July 2009
NCT01166438 Completed Phase 3 Anticholinergic vs. Botox Comparison Study March 2010 May 2012
NCT01167257 Completed Phase 2 Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome May 2010 December 2013
NCT01175382 Completed Phase 2/Phase 3 Combined Behavioral and Drug Treatment of Overactive Bladder in Men July 2010 July 2015
NCT01178827 Completed Phase 4 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial August 2010 March 2011
NCT01187082 Completed N/A Grouptraining for Overactive Bladder in Adults December 2009 March 2013
NCT01187498 Completed Phase 3 Behavioral Treatment of Overactive Bladder in Men January 2005 October 2009
NCT01214265 Completed N/A A Clinical Study for Magnetic Stimulation of the Posterior Tibial Nerve in Overactive Bladder October 2009 June 2010
NCT01220726 Completed Phase 3 Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction June 2009 November 13, 2012
NCT01294982 Completed Phase 2 Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency December 2010 November 2011
NCT01302067 Completed Phase 4 A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine May 2011 November 2012
NCT01314781 Completed Phase 4 Therapy of the Overactive Bladder Syndrome January 2012 March 2015
NCT01367886 Completed N/A Comparative Urine Proteomic Studies of Overactive Bladder in Humans August 2010 September 2011
NCT01369485 Completed N/A Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder June 2011 December 2013
NCT01437670 Completed Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin September 2011 December 2013
NCT01458197 Completed Phase 2 A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. September 2011 November 2012
NCT01488578 Completed Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) December 2006 March 2011
NCT01489709 Completed Post Marketing Survey of Vesicare in Japan June 2010 April 2011
NCT01499069 Completed N/A Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients February 2010 February 2016
NCT01512004 Completed Phase 3 Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder January 2010 August 2011
NCT01515722 Completed N/A Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder December 2010 June 2012
NCT01533597 Completed Phase 4 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB) December 2010 February 2014
NCT01539707 Completed Phase 1 Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder March 13, 2012 August 13, 2012
NCT01578304 Completed Phase 4 Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder December 2010 October 2011
NCT01628042 Completed Phase 1 A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) July 16, 2012 January 25, 2013
NCT01642277 Completed Phase 2 Bacterial Genomic Sequencing in Overactive Bladder July 2012 August 2014
NCT01644409 Completed Urgent-SQ in Treatment of Overactive Bladder Syndrome: 9-yr Follow up January 2012 July 2012
NCT01657409 Completed Phase 2 Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome August 2012 June 2014
NCT01663181 Completed Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study May 2009 April 2010
NCT01729819 Completed Phase 2 Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women January 2013 November 2014
NCT01737684 Completed Phase 1 A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) January 15, 2013 June 14, 2013
NCT06437899 Enrolling by invitation N/A Evaluation of Efficacy and Patient Satisfaction of Local Anaesthesia Versus Sedoanalgesia for Botox (R) Injection in the Urinary Bladder for the Treatment of Idiopathic Overactive Bladder September 1, 2023 September 2027
NCT06212661 Enrolling by invitation Migraine Medication Effects on Urinary Symptoms April 5, 2024 May 2026
NCT06110975 Enrolling by invitation N/A Deprescribing dRrugs for Overactive Bladder in General Practice (DROP) December 1, 2023 December 1, 2026
NCT05688644 Enrolling by invitation Sacral Neuromodulation in Neurogenic Patients December 19, 2021 December 31, 2024
NCT05576311 Not yet recruiting Codesign of an Optical Device to Measure Urine Flow and Volume November 1, 2022 February 28, 2023
NCT06181591 Not yet recruiting Phase 2 A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB) April 1, 2024 April 15, 2025
NCT06347380 Not yet recruiting N/A Usability Study of the FemPulse System April 1, 2024 August 30, 2024
NCT05672277 Not yet recruiting N/A Comparison of the Effects of Transcutaneous Electrical Nerve Stimulation Protocols in Women With Overactive Bladder February 15, 2023 February 15, 2024
NCT05903105 Not yet recruiting Diversity in Patients With OAB August 2024 December 2025
NCT05672290 Not yet recruiting N/A Comparison of the Effects of External Electrical Stimulation Protocols in Women With Overactive Bladder February 1, 2023 February 1, 2024
NCT04527445 Not yet recruiting N/A Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement June 30, 2024 June 2025
NCT05572918 Not yet recruiting Developing a Simple Test to Diagnose Overactive Bladder December 1, 2022 November 30, 2023
NCT05393921 Not yet recruiting Phase 4 The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder November 30, 2024 July 2027
NCT05977634 Not yet recruiting N/A Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder September 30, 2023 August 30, 2026
NCT05910983 Not yet recruiting N/A Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity January 1, 2025 December 1, 2025
NCT05452434 Not yet recruiting Phase 4 Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study July 15, 2022 July 15, 2023
NCT02315950 Recruiting N/A The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder December 2014 December 2025
NCT06070675 Recruiting N/A Comparison of a Paper and Automated Bladder Diary in Pediatric Patients October 1, 2023 January 1, 2026
NCT06059066 Recruiting N/A Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction October 4, 2023 October 2024
NCT06387329 Recruiting Phase 4 Bladder Botox UTI Antibiotic Prophylaxis April 4, 2024 June 30, 2025
NCT05997992 Recruiting N/A Clinical Efficacy Evaluation of Electroacupuncture as Adjuvant Therapy for Female Patients With Overactive Bladder January 11, 2023 December 31, 2023
NCT06198439 Recruiting N/A rTMS in Overactive Bladder January 8, 2024 July 2026
NCT05200923 Recruiting N/A Pelvic Health Electrically Evoked Recording (PEER) 2 Study January 18, 2022 December 18, 2026
NCT05557279 Recruiting Phase 4 Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks January 1, 2023 December 1, 2024
NCT05997043 Recruiting Early Phase 1 Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease August 26, 2023 July 1, 2026
NCT04031014 Recruiting N/A High Intensity Focused Electromagnetic Field Device for Urinary Incontinence February 1, 2020 July 2024
NCT04448171 Recruiting N/A TENS Used for Pain Management During Office Cystoscopy Botox Injections October 28, 2020 December 2025
NCT04020510 Recruiting Phase 4 Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder July 1, 2019 December 31, 2021
NCT05652023 Recruiting Noninvasive Ultrasound Assessment of Detrusor Dysfunction April 20, 2023 December 20, 2028
NCT05652036 Recruiting Phase 4 Procedural Discomfort Related to Number of Intradetrusor Botox Injections July 7, 2022 July 1, 2023
NCT06072703 Recruiting N/A Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS March 30, 2023 December 31, 2027
NCT05309993 Recruiting N/A INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder June 30, 2022 December 31, 2024
NCT06201013 Recruiting N/A Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children September 3, 2023 October 15, 2024
NCT05685433 Recruiting N/A A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE) January 26, 2023 December 2030
NCT04873037 Recruiting N/A BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder November 22, 2021 December 2025
NCT06206512 Recruiting Phase 2 Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder April 2024 March 2025
NCT05772637 Recruiting N/A Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis February 14, 2024 February 14, 2025
NCT04754737 Recruiting N/A Antibiotic Usage Prior to OnabotulinumtoxinA Injection March 23, 2021 December 2026
NCT06226220 Recruiting N/A Percutaneous Nerve Evaluation Trial Time December 10, 2023 December 31, 2024
NCT05415865 Recruiting Phase 3 The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder September 12, 2022 May 1, 2024
NCT05895045 Recruiting N/A Yoga for Treatment of Overactive Bladder in Pediatric Patients July 2024 September 2024
NCT05878951 Recruiting Phase 2/Phase 3 Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms July 13, 2023 August 24, 2024
NCT05798403 Recruiting N/A Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder July 7, 2023 March 31, 2025
NCT05799313 Recruiting N/A Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead June 7, 2023 December 2025
NCT05422625 Recruiting N/A PTNS for Female Patients Suffering From Multiple Sclerosis January 9, 2023 October 2023
NCT05362292 Recruiting Phase 4 TReating Incontinence for Underlying Mental and Physical Health October 4, 2022 December 28, 2026
NCT05844059 Recruiting Lower Urinary Tract Symptoms After Intravesical Therapy April 21, 2023 April 24, 2026
NCT05485142 Recruiting N/A The Treatment Efficacy of Prolotherapy in Bladder Voiding Dysfunction May 1, 2019 June 30, 2024
NCT05158361 Recruiting N/A Acupuncture for Overactive Bladder in Adults March 8, 2022 December 31, 2024
NCT05512039 Recruiting Phase 1/Phase 2 Reduced-dose Botox for Urgency Incontinence Among Elder Females May 12, 2023 January 1, 2027
NCT01764893 Terminated Phase 4 Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder January 2013 April 2014
NCT05381116 Terminated N/A A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder April 14, 2022 July 1, 2023
NCT00575016 Terminated Phase 2 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder December 2007 July 2010
NCT00578097 Terminated Phase 2 Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder February 2008 December 2009
NCT02398578 Terminated Phase 1/Phase 2 Cystoscopic Ablation Via RF Energy Clinical Trial February 2015 April 30, 2019
NCT00667095 Terminated Phase 3 Over Active Bladder Instillation Study - Botox April 2008 January 2012
NCT00754260 Terminated N/A Caffeine Reduction and Overactive Bladder Symptoms March 2008 June 30, 2009
NCT00759577 Terminated Phase 4 Feasibility of "At-home" Titration of Solifenacin September 2008 May 2010
NCT00780832 Terminated N/A Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder May 2008 April 2013
NCT00821184 Terminated Phase 3 Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder September 2006 September 2008
NCT00852696 Terminated N/A Over Active Bladder Patients Having Sling Surgery February 2008 February 2010
NCT00871975 Terminated Phase 4 Tetra-NIRS Clinical Study April 2009 February 2012
NCT02660138 Terminated Phase 3 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 March 2016 February 14, 2019
NCT02660359 Terminated Phase 3 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 July 8, 2016 July 4, 2019
NCT04506866 Terminated N/A InterStim Micro Post Market Clinical Follow-up Study August 25, 2020 December 8, 2023
NCT02805452 Terminated Phase 3 Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer July 2016 July 15, 2017
NCT02865395 Terminated Phase 4 Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms March 2016 June 2017
NCT01003249 Terminated Phase 4 Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen September 2009 March 2013
NCT02922842 Terminated N/A A Study of Transcutaneous Electrical Nerve Stimulation for Overactive Bladder July 2016 May 1, 2018
NCT02995967 Terminated N/A Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder November 2016 December 31, 2017
NCT03080389 Terminated Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections July 1, 2017 August 1, 2018
NCT04831801 Terminated OAB and the Microbiome June 30, 2021 November 20, 2023
NCT01189071 Terminated N/A Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain August 2009 July 2011
NCT01302938 Terminated Phase 4 Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder March 2011 August 2012
NCT01500382 Terminated Phase 1 A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) February 27, 2012 January 2, 2013
NCT01540786 Terminated Phase 1 An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics March 2012 June 2012
NCT01605617 Terminated Phase 4 Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate June 2012 March 2013
NCT00439192 Terminated Phase 2 ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB) February 2007 August 2007
NCT03508921 Terminated Phase 4 Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection July 1, 2018 June 1, 2022
NCT03523091 Terminated Phase 4 OnabotulinumtoxinA Bladder Injection Study August 8, 2018 September 1, 2020
NCT00439140 Terminated Phase 3 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder June 2007 December 2012
NCT05087810 Terminated N/A Stress and Anxiety Effects on Overactive Bladder February 16, 2023 June 5, 2024
NCT01758848 Terminated Physical Therapy for Overactive Bladder September 2010 October 2012
NCT00495053 Terminated Phase 1 Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity April 2007 November 2009
NCT03687164 Terminated N/A Group Medical Visits for Latina Women With Urgency Urinary Incontinence November 1, 2018 March 1, 2019
NCT01972061 Terminated N/A Foot/Hand Neuromodulation for Overactive Bladder (OAB) March 2014 December 11, 2018
NCT00427648 Terminated Phase 3 Local Anesthetic Treatments for Overactive Bladder March 2006 May 2010
NCT02070042 Terminated N/A Oxybutynin and Omega-3 for OAB (Overactive Bladder) February 2014 September 2015
NCT02129816 Terminated Phase 2/Phase 3 Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder May 2014 July 9, 2017
NCT02179099 Terminated Phase 1/Phase 2 Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients July 2014 February 2016
NCT00332319 Terminated Phase 2 Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients January 2006 February 2007
NCT03923348 Terminated N/A Pelvic Floor Muscle Training With Leva System for Urge Incontinence June 6, 2019 May 4, 2020
NCT00213577 Terminated Phase 2 NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder December 2003 October 2007
NCT03199443 Unknown status Standardization of Lead Placement for Sacral Neuromodulation Part 2 October 1, 2017 August 2022
NCT01409512 Unknown status Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder September 2011 September 2013
NCT01423838 Unknown status Phase 4 Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder September 2011 September 2012
NCT03260907 Unknown status N/A Efficacy and Safety of Electroacupuncture and Acupuncture in Postmenopausal Women With Overactive Bladder March 2, 2018 December 31, 2018
NCT03280316 Unknown status N/A Efficacy Comparison Between Different Management Strategies for Consistent OAB in Patients With SVMs After Surgery January 2023 December 2023
NCT00868621 Unknown status Urinary Cytokines in Patients With Overactive Bladder (OAB) March 2007 June 2009
NCT03385460 Unknown status N/A Delivery of Intravesical Botulinum Toxin A Using Low Energy Shock Waves in Treatment of Overactive Bladder: A Feasibility Study January 24, 2017 January 1, 2019
NCT03742206 Unknown status N/A Comparison of Two Forms of Transcutaneous Electrical Stimulation in Overactive Bladder January 25, 2018 October 2019
NCT04578899 Unknown status N/A "The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity" September 4, 2020 October 1, 2021
NCT02980328 Unknown status Phase 3 Low-level Light Therapy for Overactive Bladder and Urinary Incontinence December 2016
NCT02361502 Unknown status Phase 4 MIrabegron With oveRACtive bLadder Symptoms in mEn February 2015
NCT02821312 Unknown status Phase 1 A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects June 2016 April 2017
NCT02786407 Unknown status Phase 3 A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB) March 2016 December 2019
NCT02704013 Unknown status N/A Urinary Biomarkers in Overactive Bladder in Children April 2016 December 2017
NCT03061760 Unknown status Effects of Urinary Bladder Hypertrophy on Urge Urine Incontinence After Radical Prostatectomy March 1, 2017 December 31, 2019
NCT02389270 Unknown status Urinary Neurotrophin Levels in Healthy Children March 2016 December 2016
NCT03136601 Unknown status N/A Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need October 1, 2016 January 1, 2018
NCT04853849 Unknown status Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study August 26, 2021 April 30, 2024
NCT03156088 Unknown status Clinical and Urodynamic Predictors for Sacral Neuromodulation Outcomes in Overactive Bladder January 1, 2012 September 1, 2017
NCT04865328 Unknown status Impact of OAB Symptoms on Quality of Life in Croatia May 10, 2021 May 1, 2022
NCT02335853 Unknown status Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder January 2015 December 2015
NCT03194425 Unknown status N/A Standardization of Lead Placement for Sacral Neuromodulation. Part 1 September 1, 2017 August 2022
NCT03213522 Unknown status N/A Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy April 10, 2017 April 9, 2018
NCT02086058 Unknown status Gene Expression in the Overactive Bladder in Children November 2013 November 2016
NCT03412513 Unknown status Phase 4 Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease July 17, 2017 December 31, 2018
NCT03435991 Unknown status Experience Sampling Method in OAB Patients August 6, 2018 January 5, 2021
NCT02583529 Unknown status Early Phase 1 Neurogenic Overactive Bladder Treatment on Parkinson's Disease Through Back Tibial Nerve Electrostimulation July 2014 December 2017
NCT04429360 Unknown status What is the Effect of Prolapse Surgery on Voiding? June 8, 2020 June 8, 2023
NCT03829137 Unknown status N/A The Clinical Effects of Laser Acupuncture Therapy for OAB Women. January 1, 2019 April 5, 2022
NCT01569061 Unknown status N/A Painless Laser Therapy for Overactive Bladder February 2012 December 2013
NCT01613170 Unknown status Phase 4 Premarin Versus Toviaz for Treatment of Overactive Bladder April 2012 December 2018
NCT04950556 Unknown status N/A The Effects of Pelvic Floor Muscle Training in Women With Overactive Bladdder July 2021 August 2022
NCT04957524 Unknown status N/A TEST-ON - Does iStim Reduce Urinary Urgency? December 20, 2021 October 2023
NCT05337813 Unknown status N/A Effects of Low-intensity Excoporeal Shock Wave Therapy (LiESWT) on Women With Pelvic Floor Dysfunction April 10, 2020 March 31, 2023
NCT03516292 Unknown status Assessment of Potential Biomarkers in Women With Symptoms of Overactive Bladder and Pelvic Organ Prolapse January 29, 2018 December 30, 2022
NCT04364438 Unknown status N/A Effectiveness of EMS and TENS in Patients With Overactive Bladder March 3, 2020 September 2021
NCT04357223 Unknown status Phase 2 NOGO for an Overactive Bladder May 1, 2020 March 1, 2021
NCT00479596 Unknown status Phase 2/Phase 3 This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo. January 2007 May 2007
NCT02279615 Unknown status Phase 4 Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia. December 2021 December 2022
NCT03888001 Unknown status The Efficacy of Botulinum Toxin in OVERACTIVE Bladder January 1, 2018 March 1, 2020
NCT00313924 Unknown status Phase 4 Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome February 2006 March 2006
NCT05099419 Unknown status Early Phase 1 Repetitive Transcranial Magnetic Stimulation in Women With Overactive Bladder With Urgency Incontinence October 28, 2021 June 30, 2022
NCT05157295 Unknown status Phase 4 Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial January 1, 2022 September 30, 2022
NCT01842685 Unknown status N/A Bladder Thermal Distention for Patients With Refractory Overactive Bladder April 2013 April 2014
NCT03614767 Unknown status Sacral Neuromodulation & Urodynamics August 1, 2017 July 31, 2022
NCT02452879 Unknown status N/A Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study October 2014 April 2016
NCT04113941 Unknown status Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder August 23, 2019 August 2021
NCT00437528 Unknown status Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity November 2006 December 2007
NCT05240456 Unknown status Phase 1/Phase 2 Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children February 2022 December 2022
NCT04059133 Unknown status N/A The Effect of Low Intensity Extracorporeal Low Energy Shock Wave Therapy on Stress Urinary Incontinence and Overactivity Bladder February 27, 2018 July 31, 2020
NCT03695692 Unknown status N/A Effects of Connective Tissue Massage in Women With Overactive Bladder May 2, 2018 October 2019
NCT01940367 Unknown status N/A Electrical Nerve Stimulation for Overactive Bladder a Comparison of Treatments October 2013 December 2017
NCT03727711 Unknown status N/A TPTNS: Home vs Hospital Treatment for Overactive Bladder September 3, 2018 August 4, 2019
NCT02873312 Unknown status N/A Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial February 10, 2017 July 30, 2021
NCT01050114 Unknown status Phase 3 OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER August 2013 July 2018
NCT05928910 Withdrawn N/A Virtual Reality (VR) During Peripheral Nerve Evaluation (PNE) Procedure January 30, 2024 November 30, 2025
NCT05256498 Withdrawn N/A AURA 1: Augmenting Urinary Reflex Activity: Study 1 April 2022 December 2022
NCT02320201 Withdrawn N/A Foot Neuromodulation for Overactive Bladder in Children September 2014 December 2020
NCT01210859 Withdrawn Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents September 2010 December 2012
NCT03753750 Withdrawn N/A Noninvasive Spinal Cord Stimulation for Neurogenic and Idiopathic Overactive Bladder March 24, 2020 January 1, 2022
NCT00594139 Withdrawn Phase 2 Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence January 2008 January 2008
NCT03087578 Withdrawn N/A Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder July 1, 2017 September 30, 2018
NCT02297178 Withdrawn A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding August 2016 December 2016
NCT00773552 Withdrawn Phase 4 Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder November 2008 April 2009
NCT02110680 Withdrawn Phase 2 Efficacy of Transcutaneous Nerve Stimulation on Improvement of Overactive Bladder Symptoms March 2016 December 2016
NCT01003405 Withdrawn Phase 3 Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder
NCT02112786 Withdrawn N/A Neuromodulation Implantation Settings Variation for Overactive Bladder January 2015 January 2015
NCT03019094 Withdrawn N/A Overactive Bladder Posterior Tibial Implantable MIcro STimulator - 1 April 2017 December 2018
NCT02522936 Withdrawn Phase 4 Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use August 1, 2018 December 30, 2019
NCT02674269 Withdrawn Phase 1/Phase 2 Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") October 2016 October 2016
NCT00262496 Withdrawn Phase 2 Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.